18 min listen
Balancing act: Patient access and innovation
FromBioSpace
ratings:
Length:
21 minutes
Released:
Feb 7, 2024
Format:
Podcast episode
Description
This week Lori, Greg and Tyler discuss drug pricing reforms. CMS sent offers to manufacturers of the 10 drugs that have been selected for Medicare price negotiations. What's the best way forward that benefits patients while still supporting the innovation that makes these drugs possible? How will the election impact negotiations?
Also discussed earnings including Novo Nordisk, who beat analyst expectations largely due to sales of Ozempic and Wegovy, AbbVie, Merck, and GSK.
Also discussed earnings including Novo Nordisk, who beat analyst expectations largely due to sales of Ozempic and Wegovy, AbbVie, Merck, and GSK.
Released:
Feb 7, 2024
Format:
Podcast episode
Titles in the series (46)
Q3 earnings recap: winners, losers & surprises by BioSpace